Episode
On Stays Premium, Gen Z Bypasses Insurers, FDA Rethinks Psychedelics
- Podcast
- Fitt Insider
- Published
- Sep 16, 2026
- Duration seconds
- 234
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/fitt-insider-254580/episodes/on-stays-premium-gen-z-bypasses-insurers-fda-rethinks-psychedelics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/fitt-insider-254580/on-stays-premium-gen-z-bypasses-insurers-fda-rethinks-psychedelics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
September 16, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: On refuses to discount shoes as Q2 sales rise 13.5% to $1B, betting product innovation can support margins that reached 65.4% Accenture survey finds Gen Z and Millennial trust in health insurers fell 10.5%, with 62% already using AI tools to choose a health plan FDA signals more flexibility in psychedelic trial design, opening alternative approaches to comparators, dosing, and approval timelines More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → [email protected]